Ventilator-Associated Pneumonia Market Research Report - Forecast till 2030

Ventilator-Associated Pneumonia Market Research Report: Information by Diagnosis (Clinical, Radiological, Microbiological), End User (Hospitals & Clinics, Research & Academic Institutes, Ambulatory Care Centers), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2030

ID: MRFR/Pharma/0868-HCR | 110 Pages | Published By Rahul Gotadki on March 2023         

Ventilator-associated pneumonia (VAP) Market Speak to Analyst Request a Free Sample

Ventilator-Associated Pneumonia Market

The ventilator-associated pneumonia market was valued USD 988.92 million at a CAGR 10.2% by 2030

By Diagnosis Clinical Radiological Microbiological
By End User Hospitals & Clinics Research & Academic Institutes Ambulatory Care Centers
Key Players
Companies Profiled   Adenium Biotech ApS of Denmark   Crdeas Pharma of the United States   Merck and CO. Inc. of the United States   Shinogi Inc. of Japan   AstraZeneca of the United Kingdom
Market Driving Forces   Growing prevalence of ventilator-associated pneumonia   Increasing incidences of traumatic brain injury
Request a Free Sample

Ventilator-Associated Pneumonia Market Overview

The Ventilator-Associated Pneumonia Market is projected to reach USD 988.92 Million by 2030 at 10.2% CAGR during the forecast period 2022-2030. This particular type of disorder especially affects the lungs that are on ventilators. This type of disorder is caused due to the person suffering from trauma, lung disorder, and some kind of neurological disease. As per the report so published by the National Centre for Biotechnology Information (NCBI) in the year November 2017, the rise in ventilator suffering people ranges from 5% to 67%. After the incubation of the patient pulmonary disease has been increased to a wide extent. Treatment of VAP has been planned as per oxygenation, temperature, count of blood leukocyte, pulmonary radiography, and many more.

The ventilator-associated pneumonia market is anticipated to expand at a rapid rate in the upcoming future. Here the infected air passes through the endotracheal tube containing microorganisms. These microorganisms are passed to the lungs thus leading to respiratory distress. The VAP vaccines are very much important for patients in hospitals or the ones having compromised immune systems. The VAP is estimated to range from 2.13 to 116 per thousand each day.


The outburst of COVID led to the disruption in the manufacturing units. The production process from the industry was hampered. The outbreak of the pandemic brought a downfall in the economic conditions affecting the growth of the market. A declination in consumer behavior was marked. Supply chain analysis was being interrupted. The government took several necessary steps for protecting the people from COVID.

Ventilator-Associated Pneumonia Market Dynamics


Some of the driving factors like growth in prevalence of certain ventilator diseases and rise in traumatic brain injuries helps in pushing up the market size and helps in its development Crdeas Pharma of the United States. The rise in the development of research activities and the increase in expenses for the development of efficient treatment methods for the disorder helps in spurring up the ventilator-associated pneumonia market growth. Due to the unmet needs of the rising patent population the chances for expansion increase.


Some of the patients suffering from VAP have helped in rising up ICU hospitalization. Reintubation disorder, age, and some of the altered consciousness suffering from VAP and rise in mechanical ventilation along with supine position have created an opportunity for ventilator-associated pneumonia market development. The need for optical biotic treatment has risen the opportunity for market size. Adoption of reimbursement policies, adopting different technological advancement, and increase in funding ability has raised the opportunity for market growth. A rise in awareness about the disease improves growth.


The growth of the market is especially affected by the infections from the hospital patients especially ICU patients becomes the most important Challenging factor for ventilator-associated pneumonia market growth. People undergoing glucocorticoid therapy or one suffering from diabetes mellitus affect the growth and market size challenging the market. The presence of limited health resources becomes a challenging factor for the improvement of growth. Underestimation of those health resources deteriorates the growth rate.


Some of the restraining factors like spending too much on diagnostic tests, increase in charges for ventilator purposes along incorrect reimbursement scenarios will have a negative impact on ventilator-associated pneumonia market size. Some of the side effects associated with the treatment have restrained the market size. Lack of the improvement of reimbursement policies has deprived the market expansion and its growth.

Ventilator-Associated Pneumonia Market Segmentation

The ventilator-associated pneumonia market trends it has been found that the market has been classified based on diagnosis, end-users, and also based on region.

As per the diagnosis segment, the pneumonia market is being divided into a clinical segment, radiology segment, microbiological, and many more. Moreover, the microbiological segment is being bifurcated into quantitative cultures for the specimens related to airways, cultures on blood and pleural fluid, sampling of non-quantitative and semi-quantitative cultures.

As per the end-user segment it has been found that the market has been classified into research and some of the academic institutions, hospitals and medical centers, care units of ambulatory sectors, and many more.

Based on region, the market has been divided into the North American region, Latin American region. Some of the North American markets are further classified into the regions of the United States and some of the Canadian regions. Moreover, the European market covers major ventilator-associated pneumonia market share into Western Europe and Eastern Europe. The Western European market includes France, Spain, Italy, Germany, and some of the regions of the Western European region. On a regional basis, the Asia Pacific market has extended its business into the Middle East and African region. From the ventilator-associated pneumonia market outlook, it was marked that the ambulatory surgical center is being adopted to prevent the growth of microorganisms.

Technology helped in the detection of causative bacteria according to which the VAP is being denoted. The advancement of technology led to the recognition of specific bacteria. Causing respiratory disease. Technology-led to the setting up of more research institutions and labs for developing and launching innovative products. The growing technology has provided fact-based solutions to the key players.

Ventilator-Associated Pneumonia Market Regional Analysis

Regionally and geographically, from the ventilator-associated pneumonia market outlook, it was marked about the differentiation abut the market region into American region, some of the European region, Asia-Pacific along with the Middle East and African region. The United States plays a dominating role thus owing to the presence of pneumatic cases along with the rise in government initiatives along with the funds of certain non-governmental institutions for controlling the spread of disease. The European region holds the second largest ventilator-associated pneumonia market share due to the presence of certain patent populations who have lung problems and the presence of certain healthcare industries helps in driving up the market size. Moreover, the Asia Pacific region has been marked to be the largest and fastest-growing region due to the prevalence of certain infectious diseases and the presence of ventilator-associated pneumatic people.

Ventilator-Associated Pneumonia Market Competitive Landscape

Some of the key players operating in the market are Adenium Biotech ApS of Denmark, Crdeas Pharma of the United States, Merck and CO. Inc. of the United States, Shinogi Inc. of Japan, AstraZeneca of the United Kingdom, Wockhardt of the Indian region, MedImmune of the United States, Thermo Fischer Scientific of the United States, Nabriva Therapeutics  AG of Ireland and many more. These key players played a major role in building partnerships, collaborating, acquisitions, joint ventures and carried out some of the strategic analyses for playing a major role in improvement.

By taking the help of strategic analysis they carry out trending innovative procedures and manufacture the ventilators. It symbolizes and gives a neutral perspective about the industrial trends and their developments. It gives ideas about the potential and niche market segments and the regions exhibiting some of the promising ventilator associated pneumonia market growth. It gives ideas about the historical, current, and projected market structure in terms of market value and volume. These comprehensive market players offers products, and carryout certain recent developments, SWOT analysis, and some of the competitive strategies by certain key players.

Ventilator-Associated Pneumonia Market Report Overview

From the report analysis, it was found about the market drivers playing a major role in improving the growth. It signifies the growth opportunities along with the challenging factors and restraining factor that contributes to the factor affecting the strengthening position in the market. The report gives an in-depth analysis of the market segmentation. It highlights the manufacturing of innovative products from the manufacturing units.

It gives a close watch about the market share so occupied by various key players. It gives a clear overview and a geographical analysis of the market scenario and its developing structure during the ventilator-associated pneumonia market forecast period. It gives a plethora of qualitative and quantitative research and also includes the demand and supply forces that have an influential role in the market. The report gives descriptions of microbiological evidence, mortality rate, and incidence rate.

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 988.92 Million
  CAGR   10.2%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Adenium Biotech ApS (Denmark), Merck & Co., Inc. (US), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Ireland), Thermo Fisher Scientific (US), Bayer AG (Germany), Wockhardt (India), Shionogi Inc. (Japan), Cardeas Pharma (US)
  Key Market Opportunities    increasing research and development expenditure for the development of effective treatment for the disease
  Key Market Drivers

  • growing prevalence of ventilator-associated pneumonia
  • increasing incidences of traumatic brain injury

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The valuation of the ventilator-associated pneumonia market had reached USD 988.92 Million in 2030.

    Diagnosisis projected to grow at 10.2% CAGR during the assessment period (2022-2030).

    Increasing incidences of traumatic brain injury and increasing R&D expenditure for the development of effective treatment for the disease are the major tailwinds pushing the growth of the Ventilator-Associated Pneumonia Market.

    North America holds the largest share in the Ventilator-Associated Pneumonia Market, followed by Europe and the Asia Pacific, respectively.

    Adenium Biotech ApS (Denmark), Merck & Co., Inc. (US), AstraZeneca (UK), Nabriva Therapeutics AG (Austria), and MedImmune (US), are some of the major players operating in the ventilator-associated pneumonia market.